Physician profile
Amy W Boyd
NPI 1801099890
$7,813.10
in general payments reported to CMS, 2019-2025
33 companies · $782 in 2025
The $782 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $677 · 2021: $1,341 · 2022: $1,349 · 2023: $1,380 · 2024: $1,419 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,430 · Education: $134 · Consulting Fee: $16.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,430.28 |
| Education | $133.63 |
| Consulting Fee | $16.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,084.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $967.83 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $887.44 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $832.79 | 2019-2025 | Dupixent |
| Pfizer INC. | $459.27 | 2019-2025 | |
| Optinose US, INC. | $399.85 | 2019-2025 | |
| Octapharma USA, INC. | $350.85 | 2020-2024 | Cutaquig |
| Kaleo, INC. | $345.79 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $265.68 | 2020-2024 | Cuvitru, Takhzyro |
| Csl Behring | $208.20 | 2019-2025 | Hizentra, Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.68 | 2019-2023 | Spiriva Respimat |
| Grifols USA, LLC | $193.55 | 2021-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $176.81 | 2019-2025 | |
| Amgen INC. | $175.14 | 2021-2025 | Tezspire |
| Covis Pharma Gmbh | $165.47 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $157.65 | 2019-2023 | Airduo Digihaler |
| Alk-Abello, INC | $152.46 | 2021-2023 | Grastek, Ragwitek, Odactra |
| Biocryst US Sales Co., LLC | $117.81 | 2021-2024 | Orladeyo |
| Blueprint Medicines Corporation | $117.62 | 2024-2025 | Ayvakit |
| Eyevance Pharmaceuticals LLC | $77.50 | 2021 | |
| Pharming Healthcare, INC. | $76.06 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2023 | |
| Mylan Specialty L.P. | $53.53 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $50.45 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $43.11 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $36.48 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $31.74 | 2019 | |
| Shire North American Group INC | $26.34 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $20.13 | 2020 | |
| Cycle Pharmaceuticals INC | $19.83 | 2024 | Sajazir |
| Hikma Pharmaceuticals USA | $18.72 | 2025 | Ryaltris |
| Adma Biomanufacturing LLC | $16.63 | 2024 | |
| Abbvie INC. | $15.33 | 2023 | Rinvoq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.